Caribou Biosciences, Inc. (CRBU)
0.4647
0.00 (0.00%)
USD |
NASDAQ |
Oct 15, 16:00
0.4666
0.00 (0.00%)
After-Hours: 20:00
Caribou Biosciences Research and Development Expense (Quarterly) : 18.94M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 18.94M |
| March 31, 2026 | 20.61M |
| December 31, 2025 | 23.82M |
| September 30, 2025 | 22.40M |
| June 30, 2025 | 27.69M |
| March 31, 2025 | 35.53M |
| December 31, 2024 | 30.46M |
| September 30, 2024 | 30.42M |
| June 30, 2024 | 35.48M |
| March 31, 2024 | 33.79M |
| December 31, 2023 | 31.28M |
| September 30, 2023 | 28.58M |
| June 30, 2023 | 26.50M |
| Date | Value |
|---|---|
| March 31, 2023 | 25.71M |
| December 31, 2022 | 25.74M |
| September 30, 2022 | 19.99M |
| June 30, 2022 | 22.58M |
| March 31, 2022 | 13.92M |
| December 31, 2021 | 15.11M |
| September 30, 2021 | 15.83M |
| June 30, 2021 | 12.33M |
| March 31, 2021 | 10.16M |
| December 31, 2020 | 12.02M |
| September 30, 2020 | 6.18M |
| June 30, 2020 | 7.58M |
| March 31, 2020 | 8.641M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | 80.50M |
| Vir Biotechnology, Inc. | 131.35M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Oncolytics Biotech, Inc. | 4.262M |
| Sangamo Therapeutics, Inc. | 26.57M |